Veracyte Announces Global Expansion Plans with NanoString nCounter® Platform     Learn More
Veracyte Announces Global Expansion Plans with NanoString nCounter® Platform     Learn More
Skip to content
Fred Cohen
<< Back

Fred E. Cohen M.D., D.Phil.

Fred E. Cohen, M.D., D.Phil., F.A.C.P., has served as a director since January 2007. Dr. Cohen currently serves as a Cofounder and Senior Managing Partner at Vida Ventures, a life science investment group. From 2001 to 2016, he was a Partner and Managing Director of TPG Capital, a private investment firm, where he led TPG’s venture efforts in biotechnology and life sciences. From 1986 to 2016, Dr. Cohen also served as a member of the faculty of University of California, San Francisco (UCSF). At UCSF, Dr. Cohen served as an internist for hospitalized patients, a consulting endocrinologist and as the Chief of the Division of Endocrinology and Metabolism. His research interests include structure-based drug design, prion diseases, computational biology and heteropolymer chemistry. Dr. Cohen received his B.S. degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from Oxford on a Rhodes Scholarship, his M.D. from Stanford and his postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. He is a Fellow of the American College of Physicians and the American College of Medical Informatics and a member of the American Society for Clinical Investigation and Association of American Physicians. Dr. Cohen was elected to the Institute of Medicine of the National Academy of Sciences in 2004 and the American Academy of Arts and Sciences in 2008. Currently, Dr. Cohen also serves on the board of directors of Tandem Diabetes Care, Inc., UroGen Pharma Ltd., and CareDx, Inc., as well as on the boards of several privately held companies. Dr. Cohen previously served on the board of directors of Quintiles Transnational Holdings, Inc., Five Prime Therapeutics, Inc. and Genomic Health, Inc.